Internal Medicine, Infectious Disease · Wilmington, NC
NPI
1235240714
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2421 Silver Stream Ln
Wilmington, NC, 28401
Phone (910) 341-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$175K
9,440 services
Medicare patients, 2024
540
Average age 74
Drug cost, 2024
$2.3M
8,376 prescriptions
Company payments, 2025
$2,485
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul F Kamitsuka was code 36415 (venipuncture blood collection), 750 times for 337 patients. In total Paul F Kamitsuka billed 9,440 services in 89 codes, and Medicare paid $175K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-10-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 750 | 337 | $8.64 | $6,480 |
| 99214 Office E&M - Established | Office | 652 | 353 | $81.44 | $53K |
| 99232 Hospital E&M - Subsequent | Facility | 568 | 122 | $58.45 | $33K |
| 80061 Clinical Chemistry | Office | 436 | 243 | $13.12 | $5,720 |
| 85025 Blood Count | Office | 281 | 197 | $7.61 | $2,138 |
| 99213 Office E&M - Established | Office | 277 | 155 | $61.79 | $17K |
| 80053 Clinical Chemistry | Office | 277 | 195 | $10.35 | $2,867 |
| 84443 Clinical Chemistry | Office | 242 | 179 | $16.44 | $3,977 |
| 80048 Clinical Chemistry | Office | 240 | 147 | $8.29 | $1,990 |
| 84439 Clinical Chemistry | Office | 239 | 178 | $8.84 | $2,113 |
| 80076 Clinical Chemistry | Office | 224 | 152 | $8.01 | $1,794 |
| 83036 Blood Count | Office | 219 | 128 | $9.49 | $2,078 |
| 85652 Clinical Chemistry | Office | 122 | 68 | $2.65 | $323 |
| 99223 Hospital E&M - Initial | Facility | 110 | 101 | $128.74 | $14K |
| 86140 Clinical Chemistry | Office | 101 | 55 | $5.08 | $513 |
By year: 2022 $191K for 14,084 services; 2023 $190K for 11,830 services; 2024 $175K for 9,440 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 750 | 337 | $8.64 | $6,480 |
| 80061 Clinical Chemistry | 436 | 243 | $13.12 | $5,720 |
| 85025 Blood Count | 281 | 197 | $7.61 | $2,138 |
| 80053 Clinical Chemistry | 277 | 195 | $10.35 | $2,867 |
| 84443 Clinical Chemistry | 242 | 179 | $16.44 | $3,977 |
| 80048 Clinical Chemistry | 240 | 147 | $8.29 | $1,990 |
| 84439 Clinical Chemistry | 239 | 178 | $8.84 | $2,113 |
| 80076 Clinical Chemistry | 224 | 152 | $8.01 | $1,794 |
| 83036 Blood Count | 219 | 128 | $9.49 | $2,078 |
| 85652 Clinical Chemistry | 122 | 68 | $2.65 | $323 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul F Kamitsuka prescribed most often to Medicare patients was Rosuvastatin Calcium, with 559 prescriptions and refills. In total Paul F Kamitsuka wrote 8,376 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 559 | 1,590 | 162 | $7,949 |
| Atorvastatin Calcium Generic | 457 | 1,312 | 129 | $6,448 |
| Amlodipine Besylate Generic | 361 | 1,003 | 100 | $2,305 |
| Gabapentin Generic | 310 | 492 | 73 | $3,898 |
| Ezetimibe Generic | 248 | 675 | 73 | $4,056 |
| Omeprazole Generic | 248 | 711 | 77 | $3,019 |
| Losartan Potassium Generic | 199 | 584 | 61 | $2,097 |
| Levothyroxine Sodium Generic | 195 | 574 | 52 | $2,547 |
| Fluoxetine Hcl Generic | 172 | 462 | 46 | $2,501 |
| Olmesartan Medoxomil Generic | 172 | 492 | 55 | $3,071 |
| Zolpidem Tartrate Generic | 156 | 196 | 34 | $700 |
| Metoprolol Succinate Generic | 139 | 407 | 43 | $2,236 |
| Trazodone Hcl Generic | 134 | 274 | 42 | $1,039 |
| Metformin Hcl Er Metformin Hcl | 133 | 366 | 40 | $1,373 |
| Atenolol Generic | 127 | 337 | 36 | $886 |
Brand drugs: 922 claims; generic drugs: 7,399 claims; opioid claims: 63.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul F Kamitsuka $2,485 ($2,485 in general payments such as food, travel and fees) from 19 companies. The largest payer was ViiV Healthcare Company with $602.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 23 | $602 |
| Gilead Sciences, Inc. GILD | 19 | $385 |
| Merck Sharp & Dohme LLC MRK | 12 | $230 |
| Melinta Therapeutics, LLC | 9 | $210 |
| Abbvie Inc. ABBV | 11 | $166 |
| Novo Nordisk Inc NVO | 10 | $163 |
| Lilly USA, LLC LLY | 9 | $149 |
| Astellas Pharma US Inc 4503.T | 3 | $145 |
| Insmed, Inc. INSM | 4 | $88.11 |
| Pfizer Inc. PFE | 4 | $85.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.